The study is designed as a randomized, placebo-controlled, double blind, multicenter, Phase III trial to compare two COVID-19 treatment regimens in hospitalized adult subjects who are diagnosed with severe COVID 19.
Preclinical and clinical studies have demonstrated that CD24Fc effectively address the major challenges associated with COVID-19.
Coronavirus disease 2019 (COVID-19) is a respiratory illness that can spread from person to person. The virus that causes COVID-19 is a novel coronavirus that was first identified during an investigation into an outbreak in Wuhan, China.
Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 230 participants
Primary Purpose: Treatment
Actual Study Start Date: April 8, 2020
Estimated Study Completion Date: May 2022
* Additional criteria apply. Please speak with the study team for further information.
Arm A: CD24Fc/Best Available Treatment;
Arm B: placebo/ Best Available Treatment.
CD24Fc will be administered as single dose of 480 mg via IV infusion on Day 1. Total of 230 subjects will be enrolled and randomized in 1:1 ratio to receive CD24Fc or placebo. All subjects will be treated with the best available treatment. The follow up period is 15 days.
For general questions about COVID-19 clinical trials, please email [email protected] For study specific inquiries, submit the interest form and you'll be connected to the team.